{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:54:07Z","timestamp":1760295247317},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2002,4,1]],"date-time":"2002-04-01T00:00:00Z","timestamp":1017619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6490,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,4]]},"DOI":"10.1093\/annonc\/mdf056","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T22:59:57Z","timestamp":1027724397000},"page":"546-552","source":"Crossref","is-referenced-by-count":12,"title":["Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer"],"prefix":"10.1016","volume":"13","author":[{"given":"M.","family":"Venturini","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Del Mastro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"O.","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Angiolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Merlano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Bergaglio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Tolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Lambiase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Canavese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Rosso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf056_bb0010","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0959-8049(96)00492-3","article-title":"Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990","volume":"33","author":"Black","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf056_bb0015","first-page":"21","article-title":"Breast cancer: epidemiology, risk factors, screening","volume":"48","author":"Gairard","year":"1998","journal-title":"Rev Prat"},{"key":"10.1093\/annonc\/mdf056_bb0020","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3322\/canjclin.46.1.5","article-title":"Cancer statistics, 1996","volume":"46","author":"Parker","year":"1996","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 12","key":"10.1093\/annonc\/mdf056_bb0025","first-page":"1","article-title":"Current management of metastatic breast cancer","volume":"26","author":"Perez","year":"1999","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0030","first-page":"19","article-title":"Salvage chemotherapy of breast cancer","volume":"21","author":"Norton","year":"1994","journal-title":"Semin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0035","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1200\/JCO.1996.14.8.2197","article-title":"Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer","volume":"14","author":"Greenberg","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0040","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1200\/JCO.1996.14.3.764","article-title":"Effect of adjuvant chemotherapy with or without anthracyclines on the activity and efficacy of first-line cyclophosphamide, epidoxorubicin, and fluorouracil in patients with metastatic breast cancer","volume":"14","author":"Venturini","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0045","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1002\/1097-0142(20000615)88:12+<3073::AID-CNCR26>3.0.CO;2-R","article-title":"Developments in chemotherapy of breast cancer","volume":"88","author":"Hortobagyi","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf056_bb0050","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/S0959-8049(98)00058-6","article-title":"Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue","volume":"34","author":"Miwa","year":"1998","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf056_bb0055","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s002800050043","article-title":"Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients","volume":"45","author":"Sch\u00fcller","year":"2000","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1093\/annonc\/mdf056_bb0060","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Capecitabine; a review of its clinical pharmacokinetics","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"10.1093\/annonc\/mdf056_bb0065","first-page":"1013","article-title":"Induction of thymidine phosphorylase activity and enhancement of capecitabine efficacy by taxol\/taxotere in human cancer xenografts","volume":"4","author":"Sawada","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1093\/annonc\/mdf056_bb0070","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/JCO.1999.17.2.485","article-title":"Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer","volume":"17","author":"Blum","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0075","first-page":"107","article-title":"A multicenter phase II trial of Xeloda\u2122 (capecitabine) in taxane-refractory metastatic breast cancer","volume":"19","author":"Blum","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0080","first-page":"83","article-title":"Capecitabine: an active and well tolerated treatment option for patients with metastatic breast cancer recurring after taxane-containing chemotherapy. Results of a multicenter phase II trial","volume":"64","author":"Reichardt","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf056_bb0085","first-page":"121","article-title":"Capecitabine (Xeloda) as a treatment after failure to taxanes for metastatic breast cancer","volume":"19","author":"Cervantes","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 466","key":"10.1093\/annonc\/mdf056_bb0090","first-page":"19","article-title":"Capecitabine as an oral chemotherapeutic agent in the treatment of refractory metastatic breast carcinoma (MBC)","volume":"120","author":"Wong","year":"2000","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 627","key":"10.1093\/annonc\/mdf056_bb0095","first-page":"17","article-title":"A randomised, phase II study of Xeloda\u00ae (capecitabine) versus paclitaxel in breast cancer patients failing previous anthracycline therapy","volume":"163a","author":"O\u2019Reilly","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Abstr 398","key":"10.1093\/annonc\/mdf056_bb0100","first-page":"17","article-title":"A randomized phase II study of Xeloda\u2122 (capecitabine) vs CMF as first line chemotherapy of breast cancer in women aged \u226555 years","volume":"103","author":"O\u2019Shaughnessy","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0105","series-title":"Results of a large phase III trial of Xeloda\/Taxotere\u00ae combination therapy vs Taxotere\u00ae monotherapy in metastatic breast cancer (MBC) patients. Poster presented at the San Antonio Breast Cancer Symposium","author":"O\u2019Shaughnessy","year":"2000"},{"key":"10.1093\/annonc\/mdf056_bb0110","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1023\/A:1026418831238","article-title":"Dose-finding study of docetaxel and doxorubicin in first-line treatment of patients with metastatic breast cancer","volume":"10","author":"Misset","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0115","first-page":"127","article-title":"A phase III trial comparing doxorubicin (A) and docetaxel (T) (AT) to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for MBC","volume":"18","author":"Nabholtz","year":"1999","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"8","key":"10.1093\/annonc\/mdf056_bb0120","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1023\/A:1011663821703","article-title":"Identification of the highest dose of docetaxel associable with active doses of epirubicin. Results from a dose-finding study in advanced breast cancer patients","author":"Venturini","year":"2001","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0125","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1200\/JCO.1999.17.8.2341","article-title":"Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer","volume":"17","author":"Chan","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0130","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.1999.17.5.1413","article-title":"Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group","volume":"17","author":"Nabholtz","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0135","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/S0959-8049(99)00122-7","article-title":"Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group","volume":"35","author":"Sj\u00f6str\u00f6m","year":"1999","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf056_bb0140","article-title":"Aventis","author":"Docetaxel Prescribing Information","year":"2000","journal-title":"January"},{"key":"10.1093\/annonc\/mdf056_bb0145","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1634\/theoncologist.6-1-56","article-title":"The role of capecitabine, an oral, enzymatically activated fluoropyrimidine, in the treatment of metastatic breast cancer","volume":"6","author":"Blum","year":"2001","journal-title":"Oncologist"},{"key":"10.1093\/annonc\/mdf056_bb0150","first-page":"151","article-title":"Docetaxel in combination with epirubicin as first-line chemotherapy of metastatic breast cancer: final results","volume":"17","author":"Kerbrat","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0155","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1023\/A:1026437731354","article-title":"Dose-finding study of epidoxorubicin and docetaxel as first-line chemotherapy in patients with advanced breast cancer","volume":"10","author":"Pagani","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0160","first-page":"168","article-title":"Phase I study of docetaxel in combination with epirubicin as first line chemotherapy in metastatic breast cancer","volume":"17","author":"Raab","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0165","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1023\/A:1008351310818","article-title":"Front-line treatment of advanced breast cancer with docetaxel and epirubicin: a multicenter phase II study","volume":"11","author":"Mavroudis","year":"2000","journal-title":"Ann Oncol"},{"key":"10.1093\/annonc\/mdf056_bb0170","first-page":"117","article-title":"Escalating doses of docetaxel and epirubicin as first-line therapy for metastatic breast cancer. A phase I\/II study of the National Institute of Canada\u2014Clinical Trials Group","volume":"18","author":"Trudeau","year":"1999","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419618715?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419618715?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/4\/546\/560429\/mdf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:25:12Z","timestamp":1582183512000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419618715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S0923753419618715"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf056","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}